OrbiMed’s Passage Bio PASG Stock Holding History

OrbiMed’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-59,046	Closed	-$474K	–	123
2025 Q3	$474K	Sell	59,046 -243,719	-80%	-$1.7M	0.01%	107
2025 Q2	$2.42M	Sell	302,765 -48,966	-14%	-$358K	0.06%	86
2025 Q1	$2.48M	Sell	351,731 -18,512	-5%	-$200K	0.06%	89
2024 Q4	$4.2M	Sell	370,243 -120,901	-25%	-$1.57M	0.09%	90
2024 Q3	$6.88M	Sell	491,144 -15,085	-3%	-$240K	0.12%	86
2024 Q2	$8.04M	Hold	506,229	–	–	0.16%	80
2024 Q1	$13.7M	Hold	506,229	–	–	0.25%	74
2023 Q4	$10.2M	Hold	506,229	–	–	0.2%	76
2023 Q3	$6.66M	Hold	506,229	–	–	0.14%	93
2023 Q2	$9.53M	Buy	506,229 +59,629	+13%	+$1.18M	0.17%	89
2023 Q1	$8.55M	Hold	446,600	–	–	0.17%	89
2022 Q4	$12.3M	Hold	446,600	–	–	0.24%	73
2022 Q3	$11.2K	Hold	446,600	–	–	0.21%	81
2022 Q2	$21.1K	Buy	446,600 +80,000	+22%	+$3.74M	0.38%	60
2022 Q1	$22.7M	Buy	366,600 +18,455	+5%	+$1.52M	0.37%	64
2021 Q4	$44.2M	Hold	348,145	–	–	0.57%	51
2021 Q3	$69.3M	Hold	348,145	–	–	0.76%	41
2021 Q2	$92.2M	Hold	348,145	–	–	0.93%	34
2021 Q1	$122M	Hold	348,145	–	–	1.14%	25
2020 Q4	$178M	Hold	348,145	–	–	1.56%	16
2020 Q3	$91.3M	Hold	348,145	–	–	1.15%	26
2020 Q2	$190M	Hold	348,145	–	–	2.68%	9
2020 Q1	$110M	Buy	+348,145	New	+$109M	1.84%	16

Other funds holding PASG

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

YCM

Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

OrbiMed's PASG Position: Q4 2025 in Review

OrbiMed sold out of Passage Bio (PASG) in Q4 2025, closing a stake of 59,046 shares — an estimated $474K sold.

OrbiMed first reported a position in PASG in Q1 2020 and held it in 23 quarters. The position peaked at $190M in Q2 2020. 30 funds tracked by Wall St. Rank hold PASG as of Q4 2025.

OrbiMed reported no remaining Passage Bio position as of Q4 2025 after selling out during the quarter.
OrbiMed sold 59,046 Passage Bio shares in Q4 2025, an estimated $474K.
OrbiMed first reported a position in Passage Bio in Q1 2020 and held it in 23 quarters.
OrbiMed's Passage Bio position peaked at $190M in Q2 2020.
30 funds tracked by Wall St. Rank held Passage Bio as of Q4 2025.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.